The Alternative Investment Market firm has acquired technology from Swedish firm Beep Insights AB
Penarth headquartered global diagnostics firm, EKF Diagnostics, has acquired technology that tracks in real time glucose and lactate aimed at improving sport training performances.
The Alternative Investment Market listed firm has struck a deal with Sweden-based Beep Insights AB for its Beep Insights technology. The IOS and android software application combines data from sports performance wearables connected via Bluetooth with real-time glucose and lactate tracking to give personalised metrics to improve sport’s performance training.
The deal bolsters EKF’s sports performance product range, specifically its lactate scout sport, which is already compatible with the Beep Insights application – a hand-held lactate analyser.
READ MORE: Work under way on the UK’s first nuclear small modular reactors in North WalesREAD MORE: Empty building in the centre of Newport to be transformed with 750 staff moving in
EKF has been working with Peter Alex, chief executive of Beep Insights, and his team to integrate the Beep Insights tech from their software application to better determine lactate threshold in a more accessible way and improve sports training outcomes.
Following the acquisition, the value of which has no been disclosed, Mr Alex will join the EKF team and will look into developing the use of AI within performance training and how this can be integrated into the technology
Gavin Jones, chief executive of EKF said: “Whilst working with Beep Insights we have been highly impressed with how well their data handling application seamlessly connects with our handheld Lactate Scout Sport device, enabling, fast and accurate lactate threshold testing for sports performance athletes at all levels.
“The acquisition of this technology is an exciting step forward for EKF’s Sports Performance division as we look to enable athletes of all abilities access to data to drive improved training outcomes.”
Brokers Singer Capital Markets said of the deal: “Whilst we do not expect any material impact on financials in the short-term, we view this as opening an additional incremental growth driver and a positive signal of intent from management. The shares remain highly attractive with strong cash generation and a robust balance sheet.”
The broker has maintained a share price outlook of 35p.
For its 2025 financial year EKF posted revenues of £51.6m, up from £50.2m a year earlier. Its pre-tax profit of £7.1m was up from £6.3m in 2024.
Mr Jones said: “The 2025 results establish a strong foundation for the five-year strategic Development plan, providing EKF a positive base from which to push further into new markets with a simplified product offering and greater commercial focus on the areas of strategic importance.
“The trajectory for EKF has been clearly mapped to deliver further improvements in margin, revenue and Ebitda. Operational cash generation remains at a high level, and this shall be utilised to thoughtfully invest in those areas that will further build on the requirements of the strategy, and deliver long term shareholder value.
“We remain committed to establishing EKF as a true leader in Hemoglobin point-of-care testing and life sciences, further developing the business through organic growth with a strong focus on profitability improvement and sustainable investment.”






You must be logged in to post a comment Login